Business
PureTech Founded Entity Seaport Therapeutics Announces Publication in Science Translational Medicine Featuring GlyphAllo™ (SPT-300) as the First Triglyceride-Mimetic Prodrug to Achieve Therapeutically Relevant Drug Levels in Humans
BOSTON, March 25, 2026--PureTech Founded Entity Seaport Therapeutics Announces Publication in Science Translational Medicine Featuring GlyphAllo (SPT-300)
About this update from Puretech Health Plc
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":7367,"height":2362,"url":"https://media.zenfs.com/en/business-wire.com/628a893c54ff2196f8035cd4fcc7205e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/IYvWhcZzgYZfVhTtMaip8g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMwOA--/https://media.zenfs.com/en/business-wire.com/628a893c54ff2196f8035cd4fcc7205e","width":960,"height":308},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/LzlObGGiJmYz07SPq4UfvQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD03NzA-/https://media.zenfs.com/en/business-wire.com/628a893c54ff2196f8035cd4fcc7205e","width":1200,"height":385}},"lazy":false},{"type":"text","content":"BOSTON, March 25, 2026--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, notes that its Founded Entity, Seaport Therapeutics, today announced the publication of first-in-human clinical and preclinical data for GlyphAllo™ (SPT-300 or Glyph Allopregnanolone) in Science Translational Medicine.","length":472,"tagName":"p"},{"type":"text","content":"The GlyphAllo program and the underlying Glyph platform were initially advanced at PureTech, applying the Company’s strategy of identifying clinically validated pharmacology and overcoming key limitations through targeted innovation. The Glyph platform and related programs are now being advanced by PureTech’s Founded Entity, Seaport Therapeutics.","length":348,"tagName":"p"},{"type":"text","content":"The full text of the announcement from Seaport is as follows:","length":61,"tagName":"p"},{"type":"text","content":"Seaport Therapeutics Announces Science Translational Medicine Peer-Reviewed Publication Featuring GlyphAllo™ (SPT-300) as the First Triglyceride-Mimetic Prodrug to Achieve Therapeutically Relevant Drug Levels in Humans","length":218,"tagName":"p","attribs":{}},{"type":"text","content":"Newly published findings further support clinical validation of Seaport’s proprietary Glyph™ platform to enable oral dosing","length":123,"tagName":"p","attribs":{}},{"type":"text","content":"Data supported advancement of ongoing Phase 2b clinical trial of GlyphAllo in major depressive disorder (MDD)","length...